Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fluxion Delivers First Commercial Shipments of IsoFlux™ System

Published: Friday, June 07, 2013
Last Updated: Friday, June 07, 2013
Bookmark and Share
Platform enables pharma, research, and diagnostic companies to utilize blood samples for cancer diagnostic breakthroughs.

Fluxion Biosciences, Inc. has announced that the first round of IsoFlux instruments has been delivered to customers around the world.

Initially announced in November, the IsoFlux System is an automated instrument and microfluidic cartridge for high sensitivity enrichment of rare cells such as circulating tumor cells (CTCs), stem cells, and immune cells.

The first 15 instrument placements included global pharma companies, emerging biotechs, and leading cancer research institutes.

"We're very pleased that after two years of research and development, the IsoFlux System is now in the hands of very capable customers," said Jeff Jensen, CEO of Fluxion.

Jensen continued, "We fully expect that the next wave of breakthroughs in cancer diagnostics will come from this group and future customers."

CTCs are cells that disseminate from primary tumors and contribute to the spread of the disease to other parts of the body.

They circulate in very low concentration in the peripheral blood and are not readily retrievable with conventional technologies.

The IsoFlux System recovers these rare tumor cells from a standard blood draw and prepares them for molecular analysis.

The platform offers improved sensitivity of CTC recovery in a low-volume format optimized for analytical platforms such as real-time quantitative PCR (qPCR), next generation sequencing (NGS), and immunofluorescence.

Initial customers have adopted the system to characterize CTCs for biomarkers including gene expression, mutations, and chromosomal aberrations.

“Our reconnaissance identified the IsoFlux instrument as a perfectly suitable technology platform for our needs in translational cancer research to analyze circulating tumor cells from patients with various cancer indications” said Dr. Norbert Kienzle at the Ingham Institute for Applied Medical Research in Sydney, Australia.

Dr. Kienzle continued, “In addition to highly sensitive recovery of CTCs and ease of system use, we need flexibility for downstream molecular and cellular analyses - the IsoFlux ticks all these boxes. Our initial hands-on experience and the constructive working relationship with Fluxion gives us confidence to go forward with our research questions on the biology and clinical utility of CTCs, ultimately aiming to improve patient outcomes in one of Sydney’s largest and fastest growing cancer populations.”

The IsoFlux System is sold globally through Fluxion in North America and a network of distributors in Europe and Asia.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Fluxion Biosciences, UT Health Collaborate
Company has announced collaboration with UT Health to develop novel liquid biopsy approaches to improve the ability to diagnose, monitor, and treat cancer patients.
Saturday, April 30, 2016
Stanford University Study Shows Early Detection of CTCs in NSCLC Patients
IsoFlux System demonstrates high sensitivity CTC recovery in challenging patient group.
Tuesday, November 26, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!